Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

In preclinical studies, Tinostamustine has been shown to improve access to the DNA strands within cancer cells, damaging the cancer cells, DNA and preventing it from repairing itself.

SparkCures ID 225
Developed By Mundipharma EDO GmbH
Generic Name Tinostamustine
Additional Names EDO-S101
Treatment Classifications

Clinical Trials


There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Mundipharma EDO GmbH to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners